Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin
Status:
Completed
Trial end date:
2006-12-15
Target enrollment:
Participant gender:
Summary
Relacatib is being developed for the treatment of osteoporosis, osteoarthritis and possibly
other bone disorders. Recent results suggest that relacatib interacts with the way our bodies
metabolise drugs and so some drugs which are commonly prescribed to the intended target
patient population could be affected by giving relacatib at the same time. The purpose of
this study is to evaluate the effect of repeat dose administration of relacatib on the way
subjects bodies metabolise three commonly prescribed medications in the osteoarthritis
population: ibuprofen, acetaminophen, and atorvastatin.